Introduction: There are no data on the transfer of vedolizumab in breast milk of nursing mothers. We aimed to assess the presence of vedolizumab in breast milk of nursing inflammatory bowel disease [IBD] patients. Methods: This was a prospective observational study of vedolizumab-treated breastfeeding patients with IBD. Serum and breast milk samples were obtained at pre-defined tim -points. The in-house developed enzyme-linked immunosorbent assay [ELISA] for measuring vedolizumab in blood was adapted and validated for measurement of the drug in breast milk. The level of vedolizumab was also measured in breast milk of a control group of nursing healthy mothers. Results: Vedolizumab was undetectable in breast milk in IBD patients before the first infusion of vedolizumab [n = 3] and in all of the healthy controls [n = 5]. Vedolizumab was measurable in all lactating women who received vedolizumab [n = 5]. However, on serial measurements in breast milk after an infusion, drug levels did not surpass 480 ng/ml, which was roughly 1/100 of the comparable serum levels. Conclusions: Vedolizumab can be detected in the breast milk of nursing mothers. Although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro-intestinal immune-suppression of the infant.
Introduction
Inflammatory bowel disease [IBD] is highly prevalent among women in childbearing age. Thus, treatment decisions are largely influenced by patients' plans for pregnancy and lactation. 1, 2 Data assessing safety monitoring and best treatment strategies in pregnant and lactating women are still accumulating. Since breastfeeding is highly recommended as the primary form of nutrition for babies for at least the first 24 weeks of life, 3 and was not shown to have any adverse effect on disease behaviour in IBD patients, 4 it is generally advocated for IBD mothers.
Several previous studies addressed drug levels of infliximab, adalimumab, and natalizumab in breast milk and their effects on the breastfed babies. [5] [6] [7] [8] [9] Generally, no adverse consequences to babies' development and health were hitherto reported. For vedolizumab, a single previous study showed detectable drug levels in monkeys' breast milk. 10 However, to the best of our knowledge, data assessing vedolizumab levels in human breast milk are absent. Therefore, our aim was to determine vedolizumab levels in breast milk of lactating IBD mothers.
Material and Methods
This was a prospective cohort study. Patients were recruited from three tertiary gastroenterology units in Israel and the study was approved by the local ethics committee. A control group of lactating healthy individuals were also included. All patients signed an informed consent.
Study population
Breastfeeding mothers, with IBD and receiving treatment with vedolizumab, were recruited prospectively to the study from June 2016 to March 2017. Both patients who started vedolizumab treatment before pregnancy and patients starting vedolizumab postpartum where eligible for the study. All patients were treated with a standard dose of 300 mg vedolizumab intravenously per visit. Patients on maintenance therapy were treated every 8 weeks, and patients initiating vedolizumab were treated with a loading dose at Weeks 0, 2, and 6 as appropriate. Five breastfeeding healthy mothers, not exposed to immunomodulatory or biological treatment, submitted a breast milk sample for vedolizumab level testing, as controls.
Study design
Serum and first breast milk samples were collected on the day of vedolizumab treatment. Acting upon the hypothesis that breast milk levels of vedolizumab will be low, we deliberately elected to compare post-infusion milk levels with the pre-infusion blood trough levels, so as to avoid possibly down-tuning the impact of milk levels of the drug. Thus, breast milk collection was done 1 h after completion of drug infusion, whereas serum trough levels were obtained before drug infusion. Both samples were analysed for vedolizumab levels. Each breast milk sample measureded 5 ml. Consenting patients subsequently also collected sequential samples of breast milk up to 2 weeks post-infusion. Serum vedolizumab levels were not measured again in these patients.
Measurement of vedolizumab level in blood and breast milk
An in-house enzyme-linked immunosorbent assay [ELISA] for measuring vedolizumab levels was developed. Briefly, integrin alfa4-beta7 [2 µg/ml, R&D, MN, USA] was added to pre-plated anti-His-tag [4 µg/ml, R&D, MN, USA] wells of ELISA plates [Nunc, Roskilde, Denmark]. After drying, 100 μl of 1:1000 diluted serum was added and incubated for 60 min at room temperature. Plates were then washed and goat anti-human κ chain HRP-labelled antibody [Serotec, Oxford, UK] was added at a concentration of 66 ng/ml for 40 min. The results were read by an ELISA reader EL-800 [Biotek Instruments, Winooski, USA] and expressed as μg/ml. Vedolizumab concentration in serum above the cut-off value of 3 μg/ml was considered positive, as determined by three standard deviations above the mean obtained from 30 unexposed controls. To adapt the assay to measuring vedolizimab in breast milk, samples were diluted 1:5 with bovine serum albumin [BSA] and the measured levels were expressed in ng/ml.
To test the accuracy of vedolizumab concentration measurement in breast milk using our modified assay, graded exogenous vedolizumab concentrations were added to control vedolizumab-negative milk samples and a standard curve was plotted [see below]. The lower level of detection of vedolizumab in milk was 3.125 ng/ml.
Results
Eight postpartum IBD patients treated with vedolizumab were included in the study. Five of these patients conceived during vedolizumab treatment, and three patients started treatment after delivery while still breastfeeding. Table 1 shows clinical and demographic characteristics of patients enrolled. Figure 1 shows trough serum levels versus same day post-infusion breast milk levels of vedolizumab. As noted in the Methods section, we deliberately elected to measure trough serum levels [ie lowest level in serum] versus post-infusion levels in breast milk so as to reduce risk of down-playing the relative amount of drug in breast milk. Nevertheless, even using this cautious approach, serum vedolizumab trough levels reached up to 18 000 ng/ml [18 µg/ml], whereas the peak levels in breast milk samples were strikingly lower and reached up to a maximum of 478 ng/ml [ Figure 1 ]. There was no statistically significant correlation between vedolizumab trough level and same-day post-infusion breast milk level [Rho = -0.8, p = 0.11], possibly due to the already very low level of drug in milk and/or the small number of patients with dual measurements. Moreover, five patients consented to give sequential breast milk samples following drug infusion. Four of them were on vedolizumab therapy during pregnancy, and one started treatment after delivery. Vedolizumab levels in breast milk on the days following drug administration showed an upward trend in drug level until Day 3-4 post infusion, followed thereafter by a gradual decline in drug levels [ Figure 2 ]. However, in none of the patients did it exceed a level of 480 ng/ml, ie significantly lower than trough drug levels. Notably, vedolizumab was not detected in any of the five breast milk samples obtained from control healthy lactating mothers, nor in the breast milk samples obtained from three IBD patients before their first exposure to vedolizumab.
Spiking experiments by adding graded exogenous vedolizumab to control unexposed non-diluted patients' breast milk samples validated the adapted assay's ability to accurately and linearly detect concentrations of up to 100 ng/ml of vedolizumab in undiluted breast milk [ Figure 3 ]. Therefore, a 1:5 dilution was chosen and proved accurate for measuring clinically relevant drug levels in milk up to 500 ng/ml [ Figure 2 , and data not shown].
Importantly, up to 10 months' prospective follow-up showed no increase in general or gastro-intestinal tract infections in the newborns. All babies have reached the accepted development milestones.
Discussion
Human breast milk immunoglobulins are predominantly of secretory IgA class. IgG antibodies are believed to be absent from breast milk starting from a few days after delivery and thereafter. However, there is some evidence pointing to transfer of maternal IgGs in breast milk, albeit in small quantities. [11] [12] [13] Moreover, we and others have previously found infliximab and adalimumab to be present in breast milk, despite both being IgG1 monoclonal antibody drugs. 8 Nonetheless, data on breas -milk transfer of vedolizumab, another IgG1 monoclonal drug, are absent. The European Medicines Agency risk management plan [RMP] for vedolizumab states that it is not known whether vedolizumab passes into breast milk, and if it does, what effect it may have on the baby.
14 Another unknown is whether it is absorbed systemically after ingestion, if passed into the milk. Low levels [< 300 µg/L] of vedolizumab were detected on Day 28 postpartum in the milk of three of 11 cynomolgus monkeys which were treated with 100 mg/kg of vedolizumab, dosed every 2 weeks. In contrast, no drug was detected in breast milk samples from any of the primates treated with 10 mg/kg vedolizumab. 15 However, data in humans are absent.
Our report shows that vedolizumab is present in the breast milk of nursing women treated with the drug. Daily sequential vedolizumab measurement in breast milk following drug infusion allowed for a broader understanding of vedolizumab breast milk levels. It suggests that levels peak at 3-4 days following infusion to maximal levels of 480 ng/ml, and then slowly subside. Notably, milk drug levels are minute and more than two orders less than its level in serum. This low level is hypothesised to be further degraded by the newborn's intestinal proteolytic activity, thereby having a negligible impact on the infant's immune system. However, this assertion was not assessed herein directly, so further studies are warranted to address systemic effects, if any, of oral vedolizumab exposure on the suckling infant. Importantly, the presently reported babies' outcome was so far favourable, with no increase in general or intestinal infections and with no effect on general development, though caution in interpreting safety data is warranted given the cohort's size. Intriguingly, although we found that breast milk vedolizumab levels were much lower than serum levels, in some cases they were more than triple the previously published levels of infliximab in milk. This may be related to the fact that overall vedolizumab levels in serum are nearly 10 times higher than those of infliximab. 16 However, regardless of this higher level of vedolizumab compared with infliximab, it is most likely that in both cases, the impact of this miniscule drug level in milk is clinically negligible. Accumulating data from recent years showed that breastfed infants of mothers treated with infliximab or adalimumab have similar rates of growth, milestone achievement, and infection risk compared with non-breastfed infants or unexposed infants. 17 In conclusion, vedolizumab is present in minuscule levels in breast milk of nursing mothers. Previously, the cohorts that paved the way for the now widespread use of infliximab and adalimumab in breastfeeding mothers were very small in number. Similarly, we believe the present cohort, albeit small, may reassure clinicians and patients regarding the safety of breastfeeding while receiving vedolizumab. Acquisition of more data is pertinent but, if corroborated by further studies, the present findings may thereby positively impact on the lives of the many IBD patients wishing to breastfeed. 
